ROUVAX V.ruj. min. 10CCID 50 lyophilized and solvent AVENTIS
Chemical substance: live attenuated measles vaccine
ATC code: J07BD01 • Antiinfectives for systemic use | Viral vaccines | Measles vaccines
Active substance
Results for the substance live attenuated measles vaccine
2 results
About this active substance
The live attenuated measles vaccine is used to prevent measles, a highly contagious viral disease caused by the measles virus. The vaccine contains a weakened form of the virus, which stimulates the immune system to produce specific antibodies against it, providing long-term protection against infection.
The vaccine is administered subcutaneously, usually in two doses, with the first dose given at 12-15 months of age and the second between 4 and 6 years. It is recommended for children and adults who have not been previously vaccinated or have not had measles.
Common side effects include fever, rashes, pain, or swelling at the injection site. In rare cases, severe adverse reactions such as febrile seizures or allergic reactions may occur.
The live attenuated measles vaccine is an essential preventive measure for reducing the incidence of measles and its associated complications, such as encephalitis or viral pneumonia.
The vaccine is administered subcutaneously, usually in two doses, with the first dose given at 12-15 months of age and the second between 4 and 6 years. It is recommended for children and adults who have not been previously vaccinated or have not had measles.
Common side effects include fever, rashes, pain, or swelling at the injection site. In rare cases, severe adverse reactions such as febrile seizures or allergic reactions may occur.
The live attenuated measles vaccine is an essential preventive measure for reducing the incidence of measles and its associated complications, such as encephalitis or viral pneumonia.